Actively Recruiting
Advanced Fibrosis Detection for MASLD in Primary Care
Led by Medical University of South Carolina · Updated on 2026-03-31
225
Participants Needed
1
Research Sites
232 weeks
Total Duration
On this page
Sponsors
M
Medical University of South Carolina
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This proposal evaluates the implementation of a novel, non-interruptive, electronic health record alert for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk assessment in primary care patients with MASLD using a stepped wedge, cluster randomized design. This work will generate generalizable data to dramatically enhance MASLD management in primary care.
CONDITIONS
Official Title
Advanced Fibrosis Detection for MASLD in Primary Care
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a diagnosis code for MASLD
- Type 2 diabetes mellitus will
- All physicians, physician assistants, and nurse practitioners delivering primary care during the intervention phase of the study
You will not qualify if you...
- Patients with cirrhosis, complications of cirrhosis (e.g., portal hypertension, hepatic encephalopathy), hepatocellular carcinoma, or previous liver transplant
- Pregnant women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Actively Recruiting
Research Team
A
Andrew Schreiner, MD, MSCR
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here